July 25, 2016 — Varian Medical Systems announced last week that Varex Imaging Corp. will be the name for its Imaging Components business upon the completion of the planned spin-off of that business as a new, stand-alone public company via a tax-free distribution to Varian stockholders.
The U.S. Food and Drug Administration (FDA) recently approved the first focused ultrasound device to treat essential tremor in patients who have not responded to medication.
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete...
In recent years, intraoperative radiation therapy (IORT) has been growing in acceptance in the U.S. as an alternative to traditional external beam radiation therapy (EBRT) for patients with early-stage breast cancer. For patients meeting appropriate selection criteria, the benefits are clear —...
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat cancer patients for the second leading cause of death among cancer survivors — cardiovascular disease brought on by their treatments.
NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories
Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa
Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.